Last updated: February 24, 2026
What is the drug identified by NDC 00093-8740?
NDC 00093-8740 corresponds to Fendimetrazine Tartrate Extended-Release, marketed under the brand Bontril. It is a prescription medication indicated for appetite suppression as part of a weight management program.
Market Overview
Market Size and Demand
The demand for appetite suppressants like Fendimetrazine has declined due to the emergence of new obesity treatments and tighter regulatory restrictions.
- U.S. prescription volume (2022): Approx. 2 million prescriptions annually (IQVIA).
- Market penetration: Estimated at 80% for licensed weight-loss medications, with appetite suppressants representing around 15-20% of this segment.
- Growth trend: Contracting at approximately 3% annually over the past three years (EvaluatePharma).
Competitive Landscape
Competitors primarily include Phentermine, Diethylpropion, and newer GLP-1 receptor agonists such as Semaglutide (Wegovy).
| Drug Name |
Type |
Annual U.S. prescriptions (2022) |
Price Range (per 30-day supply) |
Approved Indications |
| Fendimetrazine |
Anorectic (Schedule III) |
1.2 million |
$85 - $150 |
Appetite suppression, weight control |
| Phentermine |
Anorectic (Schedule IV) |
3 million |
$10 - $50 |
Short-term weight loss |
| Semaglutide |
GLP-1 receptor agonist |
1.5 million |
$1,000 - $1,200 |
Chronic weight management |
Regulatory Environment
Fendimetrazine is classified as a Schedule III controlled substance, which limits prescribing flexibility. Recent regulatory scrutiny has targeted the abuse potential of appetite suppressants, impacting market growth.
Price Projections Analysis
Historical Pricing Trends
- Since 2018, the average wholesale acquisition cost (WAC) for Fendimetrazine has decreased from approximately $120 to $85 per 30-day supply.
- The decline aligns with increased competition and generic availability.
Future Price Trajectory (2023-2028)
Factors influencing price:
- FDA regulations: Potential for tighter control or reclassification could raise barriers, leading to price stability or increases.
- Market competition: Newer obesity drugs (e.g., Semaglutide) gain approval, shrinking the Fendimetrazine market share.
- Generic availability: Expect prices to continue declining as more manufacturers enter the generic market.
Projected WAC:
| Year |
Price Range (per 30-day supply) |
Notes |
| 2023 |
$80 - $100 |
Market stabilization, generics dominate |
| 2024 |
$70 - $90 |
Increased generic competition |
| 2025 |
$65 - $85 |
Possible regulatory tightening influencing prices |
| 2026 |
$60 - $80 |
Market saturation with generics |
| 2027 |
$55 - $75 |
Price pressure remains |
| 2028 |
$50 - $70 |
Potential decline driven by new competitors |
Price Drivers & Risks
- Manufacturing costs: Expected to decline with increased scale.
- Regulatory changes: Reclassification could either restrict or expand use.
- Market shifts: Adoption of alternative therapies could further reduce demand and pricing.
Market Entry and Investment Implications
- The current market offers limited growth prospects for Fendimetrazine due to declining demand and aggressive competition.
- Price declines are inevitable with increasing generic presence.
- Investment should consider regulatory risks and market size constraints.
Key Takeaways
- NDC 00093-8740 (Fendimetrazine) targets a shrinking appetite suppressant market.
- Prescriptions have declined, with market share targeted by newer drugs.
- Price trends forecast further reductions driven by generics and market saturation.
- Regulatory developments could impact future pricing and availability.
- Competitive landscape favors low-cost generics over branded formulations.
FAQs
1. How does the demand for Fendimetrazine compare to other appetite suppressants?
Demand for Fendimetrazine is lower than Phentermine, which has roughly double the prescription volume and broader acceptance in short-term weight-loss treatments.
2. What factors could cause Fendimetrazine's price to increase?
Regulatory tightening or reclassification that limits generic supply could reduce competition, raising prices temporarily.
3. How significant is generic competition for this drug?
Highly significant; generic versions account for over 90% of prescriptions, driving prices down.
4. Are there legal risks associated with Fendimetrazine?
Yes. As a Schedule III drug, prescribing and dispensing are tightly regulated, with potential legal risks if regulations change.
5. What alternative therapies are expected to replace appetite suppressants?
GLP-1 receptor agonists like Semaglutide are increasingly preferred due to higher efficacy and lower abuse potential.
References
[1] IQVIA. (2023). Prescription Drug Market Data.
[2] EvaluatePharma. (2022). The Future of Obesity Drugs.
[3] U.S. Food and Drug Administration. (2022). Regulatory Status of Appetite Suppressants.
[4] Medicaid and Medicare Pharmacology Reports. (2022). Price Trends in Weight Management Drugs.
